In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.
Li
Yan
Y
Discovery DMPK, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA. yan.li@astrazeneca.com
Zhou
Diansong
D
Ferguson
Stephen S
SS
Dorff
Peter
P
Simpson
Thomas R
TR
Grimm
Scott W
SW